This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1756283X08096951v1 1/3/173    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Chitturi, S. Search for Related Content Social Bookmarking                         What's this?

Treatment options for nonalcoholic fatty liver disease

Australian National University Medical School, Gastroenterology and Hepatology Unit, Canberra Hospital, Australian Capital Territory, Australia

^* To whom correspondence should be addressed.

	Abstract

Nonalcoholic fatty liver disease comprises a range of disorders from steatosis and steatohepatitis through to cirrhosis. Nonalcoholic steatohepatitis can progress to cirrhosis and liver-related death. Therefore, managing this common disorder is becoming an important public health issue. Lifestyle measures are commonly suggested but robust data are lacking. Trials with antioxidants (vitamin E, betaine) as well as cytoprotectants (ursodeoxycholic acid) have been disappointing. While data for insulin sensitizers such as metformin are less conclusive, thiazolidinediones appear promising. However, not all patients respond to thiazolidinediones. Moreover, issues related to weight gain, cardiovascular risk need to be addressed. The use of endocannabinoid antagonists and insulin secretagogues are novel strategies to combat this disorder.

Key Words: fatty liver, insulin sensitizers, nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, endocannabinoids, thiazolidinediones, ursodeoxycholic acid, vitamin E, lifestyle intervention, physical activity

First published on October 7, 2008, doi:10.1177/1756283X08096951

Therapeutic Advances in Gastroenterology 2008;1:173.

A more recent version of this article appeared on November 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?